Drugs / protective antigen
protective antigen
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00114621 | Sep 2004 → May 2011 | anthrax infection | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | protective antigen | “The active component of the investigational vaccine is called the protective antigen.” NCT00114621 ↗ |
| Known as | recombinant protective antigen | “The gene for this protein has been isolated and changed specifically to improve its properties as a vaccine-this recombinant protective antigen (rPA) elicits antibodies that...” NCT00114621 ↗ |
| Known as | rPA | “This study will examine the recombinant, that is, produced by genetic engineering, protective antigen (rPA) that brings about antibodies to neutralize the anthrax toxin and...” NCT00114621 ↗ |
| Modality | Protein / enzyme biologic | “The gene for this protein has been isolated and changed specifically to improve its properties as a vaccine-this recombinant protective antigen (rPA) elicits antibodies” NCT00114621 ↗ |